NICE Technology Appraisal No. 208; Trastuzumab for the treatment of HER-2 positive advanced gastric cancer

Provisional matrix of consultees and commentators

<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturers/sponsors</td>
<td>General</td>
</tr>
<tr>
<td>• Roche Products</td>
<td>• Allied Health Professionals Federation</td>
</tr>
<tr>
<td>Patient/carer groups</td>
<td>• Board of Community Health Councils in Wales</td>
</tr>
<tr>
<td>• Afiya Trust</td>
<td>• British National Formulary</td>
</tr>
<tr>
<td>• Black Health Agency</td>
<td>• Care Quality Commission</td>
</tr>
<tr>
<td>• Cancer52</td>
<td>• Commissioning Support Appraisals Service</td>
</tr>
<tr>
<td>• Cancer Black Care</td>
<td>• Department of Health, Social Services and Public Safety for Northern Ireland</td>
</tr>
<tr>
<td>• Cancer Equality</td>
<td>• Healthcare Improvement Scotland</td>
</tr>
<tr>
<td>• Equalities National Council</td>
<td>• Medicines and Healthcare Products Regulatory Agency</td>
</tr>
<tr>
<td>• GIST Support UK</td>
<td>• National Association of Primary Care</td>
</tr>
<tr>
<td>• Helen Rollason Cancer Charity</td>
<td>• National Pharmacy Association</td>
</tr>
<tr>
<td>• Independent Age</td>
<td>• NHS Alliance</td>
</tr>
<tr>
<td>• Independent Cancer Patients Voice</td>
<td>• NHS Commercial Medicines Unit</td>
</tr>
<tr>
<td>• Macmillan Cancer Support</td>
<td>• NHS Confederation</td>
</tr>
<tr>
<td>• Maggie’s Centres</td>
<td>• Scottish Medicines Consortium</td>
</tr>
<tr>
<td>• Marie Curie Cancer Care</td>
<td>Comparator manufacturers</td>
</tr>
<tr>
<td>• Muslim Council of Britain</td>
<td>• Abbott GmbH &amp; Co. (capecitabine)</td>
</tr>
<tr>
<td>• Muslim Health Network</td>
<td>• Accord Healthcare (5-fluorouracil, capecitabine, cisplatin, epirubicin, oxaliplatin)</td>
</tr>
<tr>
<td>• Oesophagael Patients Association</td>
<td>• Actavis UK (capecitabine, epirubicin, oxaliplatin)</td>
</tr>
<tr>
<td>• Rarer Cancers Foundation</td>
<td>• AstraZeneca (capecitabine)</td>
</tr>
<tr>
<td>• Sarcoma UK</td>
<td>• Bristol-Myers Squibb (cisplatin)</td>
</tr>
<tr>
<td>• South Asian Health Foundation</td>
<td>• Cardinal Health Martindale Products (epirubicin)</td>
</tr>
<tr>
<td>• Specialised Healthcare Alliance</td>
<td>• Fresenius Kabi (epirubicin)</td>
</tr>
<tr>
<td>• Tenero</td>
<td>• Hameln Pharmaceuticals (epirubicin)</td>
</tr>
<tr>
<td>Professional groups</td>
<td>• Hospira UK (5-fluorouracil, cisplatin, epirubicin, oxaliplatin)</td>
</tr>
<tr>
<td>• Association of Anaesthetists</td>
<td>• Krka (capecitabine)</td>
</tr>
</tbody>
</table>
| • Association of Cancer Physicians | • Medac UK (5-fluorouracil, epirubicin,
• British Psychosocial Oncology Society (BPOS)
• British Society of Gastroenterology
• Cancer Network Pharmacists Forum
• Cancer Research UK
• Royal College of Anaesthetists
• Royal College of General Practitioners
• Royal College of Nursing
• Royal College of Pathologists
• Royal College of Physicians
• Royal College of Radiologists
• Royal College of Surgeons
• Royal Pharmaceutical Society
• Royal Society of Medicine
• Society and College of Radiographers
• United Kingdom Clinical Pharmacy Association
• United Kingdom Oncology Nursing Society

Others
• Department of Health
• NHS England
• NHS Knowsley CCG
• NHS Newcastle West CCG
• Welsh Government

oxaliplatin)
• Mylan UK (epirubicin, oxaliplatin)
• Pfizer (cisplatin, epirubicin)
• Roche Products (capecitabine)
• Sandoz (cisplatin)
• Sanofi (oxaliplatin)
• Strides Arcolab (epirubicin)
• Sun pharmaceuticals (oxaliplatin)
• Teva UK (capecitabine, cisplatin, epirubicin, oxaliplatin)
• Wockhardt UK (5-fluourouracil, cisplatin, epirubicin, oxaliplatin)
• Zentiva UK (oxaliplatin)

Relevant research groups
• Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
• CORE- Digestive Disorders Foundation
• Health Research Authority
• Institute of Cancer Research
• MRC Clinical Trials Unit
• National Cancer Research Institute
• National Cancer Research Network
• National Institute for Health Research
• Research Institute for the Care of Older People

Assessment Group
• Assessment Group tbc
• National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups
• National Clinical Guidelines Centre
• National Collaborating Centre for Cancer

Associated Public Health Groups
• Public Health England
• Public Health Wales NHS Trust
NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS
Definitions:

Consultees
Organisations that accept an invitation to participate in the appraisal: the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).
All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators
Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary. All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group
An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.